Key result
Preference-based antithrombotic therapy improved quality-adjusted survival by 0.05 QALY and saved $670 in patients with nonvalvular atrial fibrillation and no other stroke risk factors.
Why the study?
Does preference-based antithrombotic therapy improve quality-adjusted survival and reduce medical expenditure compared to warfarin-for-all in patients with nonvalvular atrial fibrillation?
Does preference-based antithrombotic therapy improve quality-adjusted survival and reduce medical expenditure compared to warfarin-for-all in patients with nonvalvular atrial fibrillation?
Incorporating patient preferences into antithrombotic therapy selection for nonvalvular atrial fibrillation improves quality-adjusted survival and reduces costs, particularly in patients with one or fewer additional stroke risk factors.
No takes yet. Share an insight, caveat, or question.
May support preference-based selection in low-risk AF; reinforces guidelines but leaves prospective validation open.
Gage et al. (1998) studied Nonvalvular atrial fibrillation. Preference-based antithrombotic therapy vs. Warfarin-for-all therapy was evaluated on Quality-adjusted survival and medical expenditure. Preference-based antithrombotic therapy improved quality-adjusted survival by 0.05 QALY and saved $670 in patients with nonvalvular atrial fibrillation and no other stroke risk factors.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: